ANNAPOLIS, MD (June 5, 2013) – Governor Martin O’Malley today announced that Rachel King, co-founder and CEO of GlycoMimetics in Gaithersburg, has been named chair of the Maryland Life Sciences Advisory Board (LSAB). King will replace chair H. Thomas Watkins, former President and Chief Executive Officer of Human Genome Sciences, Inc., who has served on the Board since Governor O’Malley and the Maryland General Assembly created it in 2007. As chair, Watkins led the Board through a strategic planning process that, working closely with Governor O’Malley, resulted in BioMaryland 2020, a 10-year, $1.3 billion strategy for moving Maryland’s life sciences industry forward.
“I want to commend Tom for leading the effort to develop a comprehensive plan that has helped position Maryland as a global leader in the life sciences. To date, we have invested more than $600 million in initiatives that create jobs and expand opportunity for decades to come,” said Governor O’Malley. “We are equally fortunate to have someone of Rachel’s caliber as our new chair, as well as a board comprised of some of the State’s most skilled and talented scientists, educators and business professionals to help us grow our Innovation Economy.”
“It was an honor to serve as Board chair and work with many dedicated colleagues and industry leaders to maximize Maryland’s tremendous life sciences assets and build a roadmap for the industry’s future,” said Watkins. “I also want to thank Governor O’Malley for his vision for the life sciences in Maryland and for his continued support, which has resulted in making our State one of the top science and technology states in the country.”